RxDoctor Payments Data

Joseph Camero, MD

Neurology · Laredo, TXNPI 1548373996

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 58 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$530
  • Livanova USA, Inc.$263
  • Eisai Inc.$180
  • Novartis$147
  • Argenx US, Inc.$147
  • Otsuka America Pharmaceutical, Inc.$83
  • plus $260 from 7 others

What the payments were for

  • Food & beverage$1,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$361,866
Medicare patients
599
Services billed
3,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole57$87,673
EliquisApixaban102$59,580
FycompaPerampanel48$55,505
BelsomraSuvorexant37$19,839
Entacapone121$14,153
UbrelvyUbrogepant12$13,624
Levetiracetam253$7,339
Lacosamide37$7,279
JardianceEmpagliflozin11$6,263
Carbamazepine88$4,748
Oxcarbazepine66$4,547
Memantine Hcl243$4,295
Donepezil Hcl682$3,956
Gabapentin374$3,675
Carbidopa-LevodopaCarbidopa/Levodopa229$3,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$83$87,67357 claims
PfizerEliquis$44$59,580102 claims
Eisai Inc.Fycompa$180$55,50548 claims
AbbVieUbrelvy$78$13,62412 claims
Lilly USA, LLCOlanzapine$530$1,73779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,246 neurology providers in Texas.

Other neurology in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →